- The Myeloma Beacon - https://myelomabeacon.org -
Atiprimod (azaspirane, SK&F106615)
By: Admin; Published: October 15, 2008 @ 8:00 am | Comments Disabled
Brand Name: | Atiprimod |
Generic Name: | azaspirane |
Code Name: | SK&F106615 |
Company: | Callisto Pharmaceuticals |
FDA Clinical Phase: | 1/2 |
Description:
Atiprimod is a type of signal transduction inhibitor. It is being studied in the treatment of certain multiple myelomas and other advanced cancers. Atiprimod may block the growth of tumors and the growth of new blood vessels that tumors need to grow.
Clinical Trials:
For a list of clinical trials studying Atiprimod for the treatment of multiple myeloma, see ClinicalTrials.gov [1].
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2008/10/15/atiprimod/
URLs in this post:
[1] ClinicalTrials.gov: http://www.clinicaltrial.gov/ct2/results?term=&recr=&rslt=&type=&cond=multiple+myeloma&intr=Atiprimod&outc=&lead=&spons=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&rcv_s=&rcv_e=&lup_s=&lup_e=
[2] http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Atiprimod: http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Atiprimod
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.